Surprisingly, we found that CD25 (Fig. 2A), CTLA4 (Fig. 2B), GITR (Fig. 2C), and CD39 (Fig. 2D), and foxp3 (Fig. 2E) mRNA levels were significantly increased in PBMCs from MS patients experiencing a clinical relapse, as compared to patients in a stable phase of the disease. Here, CTLA4 is linked to myeloid sarcoma.